Home » Coronado Biosciences Debuts on Nasdaq, Moves Two Lead Drugs Forward
Coronado Biosciences Debuts on Nasdaq, Moves Two Lead Drugs Forward
The path to becoming a publicly listed company chosen by Coronado Biosciences was anything but conventional, but it seems to be working for the biotech startup. After raising $47.4 million privately over the last year, the company filed a Form 10 with the SEC so it could become a public company by registering all its private shares as common stock, rather than undergoing a typical, underwritten IPO.
Xconomy
Xconomy
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May